Thursday, 15 October 2026European Markets

FINATIS Stock Bullish By 34% In The Last 21 Sessions

Loading stream...

(vianews) - shares of finatis (cac 40: fnts.pa) jumped by a staggering 34.45% in 21 sessions from €5.95 to €8.00 at 16:55 est on friday, after two sequential sessions in a row of gains. cac 40 is sliding 1.79% to €6,899.85, following the last session's upward trend.

about finatis

finatis société anonyme engages in food distribution activities in france and latin america. it operates monoprix, franprix, casino supermarkets, petit casinos, casino shops, spars, vivals, géant hypermarkets, etc. the company also distributes sports equipment under the go sport brand; and invests in real estate properties, as well as manages a portfolio of private equity investments. as of december 31, 2019, it operated a portfolio of 11,172 stores. the company is based in paris, france. finatis société anonyme is a subsidiary of euris sas.

earnings per share

as for profitability, finatis has a trailing twelve months eps of €-32.99.

volume

today's last reported volume for finatis is 25 which is 90.15% below its average volume of 254.

more news about finatis (fnts.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com